Revenue Update on Masimo Corporation(NASDAQ:MASI)

Masimo Corporation(NASDAQ:MASI) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $172.64M. Analysts estimated a revenue of $166.02M. Earnings per share were $0.49. Analysts had estimated an EPS of $0.41.

Masimo Corporation (MASI) made into the market gainers list on Fridays trading session with the shares advancing 0.21% or 0.12 points. Due to strong positive momentum, the stock ended at $58.24, which is also near the day’s high of $58.61. The stock began the session at $58.11 and the volume stood at 4,04,434 shares. The 52-week high of the shares is $59.18 and the 52 week low is $33.03. The company has a current market capitalization of $2,874 M and it has 4,93,51,459 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jul 1, 2016, Ramshorst David J Van (Chief Accounting Officer) sold 5,000 shares at $52.50 per share price.Also, On Jun 8, 2016, Joe E Kiani (CEO and Chairman of the Board) sold 65,048 shares at $50.00 per share price.On Jun 2, 2016, Jon Coleman (Pres-WW Sales,Pro Svc,Med Affs) sold 4,000 shares at $50.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Masimo Corporation is a global medical technology company that develops manufactures and markets non-invasive patient monitoring products. The Company’s core business is measure-through-motion and low-perfusion pulse oximetry monitoring known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive optical blood constituent monitoring optical organ oximetry monitoring electrical brain function monitoring acoustic respiration monitoring and optical gas monitoring. In addition the Company offers Root patient monitoring and connectivity platform the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. The Company also has the Patient SafetyNet remote patient surveillance monitoring system which allows up to 80 patients to be monitored simultaneously through a central station or remotely by care providers through their pagers or smart phones.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Masimo Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Masimo Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.